BioPharma Clinical Trials

Aptamer and Neuro-Bio enter the second phase of Alzheimer’s test development

This latest phase involves development of an additional Optimer binder against the innovative Neuro-Bio target implicated in Alzheimer’s disease, wit...

 February 23, 2024 | News

Mabwell's Novel ADC 7MW3711 for Advanced Malignant Solid Tumors Receives FDA Clinical Trial Approval

 Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its clinical trial application of B7-H3 targe...

 February 21, 2024 | News

Innovent's IBI311 Clears Phase 3 Hurdle for Thyroid Eye Disease with Promising Results

The trial also successfully met its key secondary endpoints, including the overall response rate, the percentage of subjects achieving a clinical activity ...

 February 20, 2024 | News

Japan Accelerates Approval Process for Groundbreaking Urothelial Cancer Treatment by Astellas

Astellas Pharma Inc. (TSE:4503, President and CEO: Naoki Okamura, "Astellas")  announced that Japan's Ministry of Health, Labour a...

 February 19, 2024 | News

Jacobio Gains China CDE Approval for Phase III SHP2 and KRAS G12C Inhibitor Trial

This approved study in China is a randomized active controlled phase III trial design to evaluate the efficacy and safety of JAB-3312 in combinat...

 February 19, 2024 | News

FDA Prioritizes Review of Bristol Myers Squibb's Augtyro™ for NTRK-Positive Solid Tumors

Bristol Myers Squibb (NYSE: BMY) announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) for A...

 February 15, 2024 | News

BioAge Secures $170 Million in Series D Funding to Propel Obesity and Metabolic Disease Drug Development

  BioAge Labs (“BioAge”), a pioneering biotechnology firm dedicated to advancing novel treatments for obesity and metabolic diseases by e...

 February 14, 2024 | News

Brii Biosciences Secures Intellectual Property Rights for HBV Treatment from VBI Vaccines

Brii Biosciences Limited ("Brii Bio"), a leader in developing innovative treatments for diseases with significant unmet needs, has announced a strategic ac...

 February 14, 2024 | News

Otsuka's AVP-786 Falls Short in Phase 3 Trial for Alzheimer's Agitation

Otsuka Pharmaceutical Development & Commercialization, Inc., (OPDC) and its parent company Otsuka Pharmaceutical, Co. Ltd. (Otsuka) have released the t...

 February 13, 2024 | News

Gilead Sciences Bolsters Liver Portfolio Through Acquisition of CymaBay Therapeutics

    Gilead Sciences, Inc. and CymaBay Therapeutics, Inc. announced today a definitive agreement whereby Gilead will acquire CymaBay for $32.50 ...

 February 13, 2024 | News

CSL Reveals Phase 3 AEGIS-II Trial Results for CSL112

"We look forward to sharing our scientific learnings regarding cholesterol efflux and recurrent cardiovascular events," said C. Michael Gibson, M.S., ...

 February 12, 2024 | News

Zymedi initiates first human dosing of ZMA001 in a clinical trial for Pulmonary Arterial Hypertension in South Korea

  In collaboration with the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH), Zymedi is conducting this t...

 February 09, 2024 | News

SMC Laboratories Unveils STAM™-HCC/IO+ Mouse for Advancing Liver Cancer Drug Development in Immuno-Oncology

 The company specializes in liver-related services and has evaluated test substances in over 15 MOA categories as well as over 270 target molecules us...

 February 07, 2024 | News

ShiraTronics finishes Australian pilot study enrollment, gears up for pivotal clinical trial

Migraine, recognized globally as a significant cause of disability, particularly among pre-menopausal women, poses a substantial health challenge. For arou...

 February 07, 2024 | News

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in